Project Grant R44AG092185
Award Date 9/10/25
Completion Date 8/31/26
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- This Project Grant award of $576,664 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Janusq LLC is funding research to evaluate the pharmacokinetics and in vivo efficacy of a macrocyclic peptide therapy (DA45) for treating mitochondrial dysfunction in Alzheimer's disease. The two-year project will assess the peptide's exposure, stability, and therapeutic effects in a mouse model of Alzheimer's, using advanced analytical methods to quantify DA45 levels in plasma and brain...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This $495,699 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) on September 20, 2025. The grant supports the development of a drug candidate, PGI-5128, for the treatment of agitation in Alzheimer's disease. The primary objectives are to: 1) Evaluate the efficacy of PGI-5128 in reducing aggressive behaviors in transgenic Alzheimer's disease mouse models, and 2) Initiate investigational new drug (IND)-enabling...
- This $8.13 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports clinical development activities for PTI-125, an investigational Alzheimer's disease therapeutic under development by Cassava Sciences, Inc. The funding will enable Cassava Sciences to conduct a food effect study to determine the impact of food on PTI-125 absorption, as required by the U.S. Food and Drug Administration. Additionally, the company will scale up...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...